Antibody Appeals Uncovered Report

Since the first approval of Muromonab-CD3 in 1986, antibodies have become progressively more common, frequently reaching a ‘blockbuster’ status. According to statistics provided by Statista in March, 5 out of 10 top-selling drugs were antibodies in 2023. Therefore, patents related to antibodies are now of considerable interest and significance to the pharmaceutical industry. They provide protection for commercially important inventions, spur further investment, and allow patients to benefit from these therapeutics. Our report provides a high-level analysis of the Board of Appeal decisions in this technical area and identifies notable trends and other useful information.